Press Releases

17
 InNexus Bio Expands Team to Focus on Licensing and Partnering
03
 InNexus Bio Provides Summary of 2010 Accomplishments and 2011 Outlook
09
 InNexus Biotechnology Awarded Federal Grant
01
 InNexus will delay filing its annual financial reports from October 28 to December 31 2010
02
 Annual Shareholders' Meeting of InNexus Biotechnology: Shareholders Approve All Resolutions
01
 InNexus Biotechnology Amends Collaborative Agreement with the National Cancer Institute (NCI)
29
 InNexus Announces Discovery of Novel Protein for AMD Eye Disorder
27
 InNexus Biotechnology Signs Collaboration Agreement with the National Cancer Institute
18
 InNexus Biotechnology Announces Shares issued for Bridge Loan Payments and Non-brokered Private Placement
04
 InNexus Relocates to Tech Incubator in Chandler, Arizona
23
 InNexus Bio DXL™ Antibody Technology Causes Cancer Cell Death By Mechanisms Not Seen with Current Market-Leading Medications
23
 InNexus Biotechnology Announces Increase in Loan Facility of USD$1.0 Million
05
 InNexus Biotechnology Develops New Psoriasis Product Based on Its Skin Permeating Antibody Technology
31
 INNEXUS Promotes Canadian TSX Venture Exchange Listing With Investors
10
 InNexus and Xeris Announce Research Collaboration
02
 InNexus Biotechnology Issues a Shareholder Update
05
 Business Development Initiative for DXL625, Royalty Pharma Comments
16
 Renowned Cancer Researcher Dan Von Hoff, M.D. Joins InNexus Scientific Board
10
 InNexus and Genhelix to Combine Antibody Development and Manufacturing Resources
30
 Annual Shareholders’ Meeting of InNexus Biotechnology Inc: Shareholders Approve All Resolutions
20
 AACR 10th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL with Safety Comparable to Approved Antibody Therapies in Preclinical Studies
09
 AACR Data Highlights InNexus' Preclinical Antibody Candidate
25
 InNexus Biotechnology Announces a Loan Facility of up to USD$2.5 Million
06
 InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL™ Antibodies
03
 FDA Provides a Positive Review of InNexus Biotechnology Development Plan for Lead Product
04
 InNexus Biotechnology CEO To Present at the 11th Annual BIO CEO Conference
27
 InNexus Completes Previously Announced Private Placement
13
 InNexus Biotechnology Completes Preclinical Study Confirming In Vivo Effectiveness and Safety of Lead Candidate DXL625, Schedules Meeting with FDA
12
 InNexus Completes Previously Announced Private Placement
17
 InNexus Biotechnology CEO Named Business Leader of the Year
07
 InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and announces $1.25 Million Private Placement
30
 InNexus Biotechnology Receives Patent Grants in Europe
28
 InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
29
 InNexus Biotechnology CEO To Present at BioContactQuebec 2008
19
 St. Joseph's Hospital and InNexus Biotechnology Enter Collaborative Partnership
16
 InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
09
 InNexus Biotechnology Strengthens Patent Team with New Leadership
08
 InNexus Biotechnology CEO To Present at The Wall Street Analyst Forum in NYC
07
 InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
06
 InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds
31
 InNexus To Present at 2008 DDT Aug 6th in Boston
23
 InNexus Biotechnology Announces Completion of Brokered Private Placement
12
 InNexus Biotechnology Announces Expansion of Patent Protection of DXL™ Technology
02
 InNexus Biotechnology Launches Competitive Summer Intern Program: LABapprentice
30
 InNexus Biotechnology Announces Oversubscription of Private Placement Raised to $5 Million and Additional Equity Financing up to $7.5 Million
23
 InNexus Biotechnology Announces Brokered Private Placement with Dundee Securities Corporation
12
 InNexus Biotechnology CEO and Scientific Advisory Board Chairman to Present at Global HealthCare and Financial Conferences
08
 InNexus Biotechnology Hosts Inaugural Event of U.S. Department of Commerce
07
 InNexus Biotechnology Receives 2008 Frost & Sullivan Innovation of the Year Award
07
 InNexus Biotechnology Launches Competitive Summer Intern Program -- LABapprentice
15
 InNexus Biotechnology Presents Proof of Principle Data at AACR
21
 InNexus Biotechnology Holds Annual General Meeting and Receives Overwhelming Mandate from Shareholders
14
 InNexus Biotechnology Engages Dundee Securities Corporation as Strategic Financial Advisor
12
 InNexus Biotechnology Announces Genetically Engineered DXLmouse™ Platform
28
 InNexus Biotechnology Develops Diagnostics Business Based on DXL™ Technology
27
 InNexus Biotechnology Inc. Announces Earnings for the Second Quarter Ended December 31, 2007
19
 InNexus Biotechnology Announces Second Preclinical Candidate DXL702 (HER2/neu) Targeting Breast Cancer. Will Host Scientific Teleconference to Discuss latest Product and Progress of DXL™ Pipeline
11
 InNexus Biotechnology Welcomes Dr. Ronald Levy, Stanford University School of Medicine Oncology Division Chief to Scientific Advisory Board
07
 ROYALTY PHARMA AND INNEXUS BIOTECHNOLOGY ANNOUNCE AGREEMENT REGARDING THE PURCHASE OF A SECOND ROYALTY RIGHT BASED ON INNEXUS’ DXL™ ANTIBODY TECHNOLOGY
29
 Three Leading Pharmaceutical Trade Publications Highlight InNexus’ Proprietary Technology, Dynamic Cross Linking
22
 InNexus Biotechnology Announces Dr. Capra Has Joined its Board of Directors